AstraZeneca’s NSCLC treatment Tagrisso (Osimertinib) succeeded in renewing its risk-sharing agreement (RSA) with the National Health Insurance Service, and the price of the drugs will be adjusted and discounted by 3% per dose.

According to industry sources, AstraZeneca has agreed to discount the insurance price of Tagrisso during RSA renegotiations with the NHIS. With the MOHW working to amend the ‘drug reimbursement list and reimbursement ceiling price table’ to implement these changes. If the amendment is finalized, it can be applied from March 1st.

Leclaza is reimbursed for second-line treatment of lung cancer, for locally advanced or metastatic non-small cell lung cancer (N